SG11202104833YA - Use of dantrolene and dantrolene prodrugs to treat radiation exposure - Google Patents

Use of dantrolene and dantrolene prodrugs to treat radiation exposure

Info

Publication number
SG11202104833YA
SG11202104833YA SG11202104833YA SG11202104833YA SG11202104833YA SG 11202104833Y A SG11202104833Y A SG 11202104833YA SG 11202104833Y A SG11202104833Y A SG 11202104833YA SG 11202104833Y A SG11202104833Y A SG 11202104833YA SG 11202104833Y A SG11202104833Y A SG 11202104833YA
Authority
SG
Singapore
Prior art keywords
dantrolene
prodrugs
radiation exposure
treat radiation
treat
Prior art date
Application number
SG11202104833YA
Inventor
Adrian Hepner
Original Assignee
Eagle Res Labs Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eagle Res Labs Limited filed Critical Eagle Res Labs Limited
Publication of SG11202104833YA publication Critical patent/SG11202104833YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SG11202104833YA 2018-11-27 2019-11-27 Use of dantrolene and dantrolene prodrugs to treat radiation exposure SG11202104833YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862772001P 2018-11-27 2018-11-27
PCT/US2019/063503 WO2020112932A1 (en) 2018-11-27 2019-11-27 Use of dantrolene and dantrolene prodrugs to treat radiation exposure

Publications (1)

Publication Number Publication Date
SG11202104833YA true SG11202104833YA (en) 2021-06-29

Family

ID=69024602

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104833YA SG11202104833YA (en) 2018-11-27 2019-11-27 Use of dantrolene and dantrolene prodrugs to treat radiation exposure

Country Status (13)

Country Link
US (1) US20220023319A1 (en)
EP (1) EP3886846A1 (en)
JP (1) JP2022509176A (en)
KR (1) KR20210096152A (en)
CN (1) CN113164449A (en)
AU (1) AU2019387225A1 (en)
BR (1) BR112021010105A2 (en)
CA (1) CA3120986A1 (en)
IL (1) IL283061A (en)
MA (1) MA54303A (en)
MX (1) MX2021006162A (en)
SG (1) SG11202104833YA (en)
WO (1) WO2020112932A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150231093A1 (en) * 2014-02-17 2015-08-20 The University Of Chicago Methods and compositions for countermeasures against radiation
KR102652642B1 (en) * 2017-10-20 2024-04-01 이글 리서치 랩스 리미티드 Dantrolene prodrug and method of use thereof

Also Published As

Publication number Publication date
WO2020112932A1 (en) 2020-06-04
CA3120986A1 (en) 2020-06-04
IL283061A (en) 2021-06-30
BR112021010105A2 (en) 2021-08-24
AU2019387225A1 (en) 2021-06-10
MX2021006162A (en) 2021-08-16
JP2022509176A (en) 2022-01-20
EP3886846A1 (en) 2021-10-06
MA54303A (en) 2021-10-06
CN113164449A (en) 2021-07-23
KR20210096152A (en) 2021-08-04
US20220023319A1 (en) 2022-01-27

Similar Documents

Publication Publication Date Title
SG11202002919PA (en) Techniques and apparatuses for beam management to overcome maximum permissible exposure conditions
RS64218B1 (en) Combination of anti-pd-1 antibodies and radiation to treat cancer
IL268138A (en) Combinations of cabozantinib and atezolizumab to treat cancer
IL274045A (en) Dantrolene prodrugs and methods of their use
IL290321A (en) Use of sepiapterin and metabolites thereof to treat radiation exposure
GB201804514D0 (en) Treatment of pyroptosis
GB2577661B (en) Determination of lithography effective dose uniformity
IL274532A (en) Use of riluzole prodrugs to treat ataxias
GB201505860D0 (en) Therapeutic compositions and methods of use for treating cancer
EP3477343A4 (en) Gel forming composition for radiation dosimetry and radiation dosimeter using gel that is formed from said composition
ZA201903795B (en) Treatment of water
IL276203A (en) Compositions and methods of treating cancer
GB201804515D0 (en) Treatment of necroptosis
GB2562661B (en) Oil palm phenolics composition for the protection of human organs, cells and tissues against the injurious effects of exposure to ionizing radiation
IL278978A (en) Compositions and methods for treatment of psoriasis
IL283061A (en) Use of dantrolene and dantrolene prodrugs to treat radiation exposure
GB201904758D0 (en) Xyloglucan-containing prodrugs and methods of manufacture and use thereof
IL272847A (en) Methods of using dantrolene to treat nerve agent exposure
IL281284A (en) Methods of treating psoriasis
SG11202011121UA (en) Dantrolene formulations and methods of their use
ZA202100752B (en) Treatment and prevention of injury due to radiation exposure
IL275913A (en) Methods and combination therapy to treat cancer
IL283912B (en) Methods of treating cancer using platanoside and isomers thereof
IL272018A (en) Radiation dosimeter and method of operation6545
GB201815000D0 (en) Treatment of hypothroidism and related conditions